Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma

Steven Brem, Stuart A. Grossman, Kathryn A. Carson, Pamela New, Surasak Phuphanich, Jane B. Alavi, Tom Mikkelsen, Joy D. Fisher

Research output: Contribution to journalArticle

Abstract

Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83% of these patients. Normal serum copper levels at baseline (median, 130 μg/dl; range, 50-227 μg/dl) fell to the target range of <50 μg/dl (median, 42 μg/dl; range, 12-118 μg/dl) after two months. Penicillamine-induced hypocupremia was well tolerated for months. Drug-related myelosuppression, elevated liver function tests, and skin rash rapidly reversed with copper repletion. Median survival was 11.3 months, and progression-free survival was 7.1 months. Achievement of hypocupremia did not significantly increase survival. Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme.

Original languageEnglish (US)
Pages (from-to)246-253
Number of pages8
JournalNeuro-oncology
Volume7
Issue number3
DOIs
StatePublished - Jul 1 2005

Keywords

  • Angiogenesis
  • Brain tumor
  • Copper
  • Glioblastoma
  • Penicillamine

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma'. Together they form a unique fingerprint.

  • Cite this